Ok

By continuing your visit to this site, you accept the use of cookies. These ensure the smooth running of our services. Learn more.

Cancer Supportive Care Drugs Market: Revenue and growth prediction till 2026 with covid-19 impact analysis

March 07, 2023/Industry News Global/ -- This new report from Stratview Research analyses the Cancer Supportive Care Drugs Market over the forecast period from 2022 to 2028. The insights of the report shall enable informed decision-making and strategy formulation for the near future to capitalize on the opportunities.

Cancer Supportive Care Drugs Market Overview:

The cancer supportive care drugs market was estimated at US$ 20.9 billion in 2021 and is expected to grow at a CAGR of 2.04% during 2022-2028 to reach US$ ~21.40 billion in 2028.

Drivers

The following are the major players in the cancer supportive care drugs market:

  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc (GSK)
  • Helsinn Healthcare SA
  • Heron Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG

Rising technological and therapeutic developments as well as an increase in product launches by market participants are factors driving the growth of the global market for asthma and COPD medications. For the introduction of new products, certain governmental organisations work with industry participants.

Segment Analysis

Based on drug class, application, distribution channel, and geography, the market has been divided into segments. On the basis of drug class, the market has been segmented into G-CSFs (Granulocyte-colony Stimulating Factors), ESAs (Erythropoiesis Stimulating Agents), anti-emetics, bisphosphonates, opioids, NSAIDs, and others. The Granulocyte Colony Stimulating Factor (G-CSF) category had the highest revenue. It is the main option for treating neutropenia brought on by cancer. It is one of the most frequently prescribed supportive care medications for lymphoma and breast malignancies. For instance, in the UK, G-CSF is given to 84% of patients with lymphoma and 70% of breast cancer patients, respectively. However, the declining usage of myelosuppressive chemotherapy, which limits the formation of G-CSF, is a consequence of the increased use of immuno-oncology (IO) drugs in therapy, such as anti-PD-1/L1s. During the anticipated term, positive growth in the antiemetics segment is anticipated.

Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent issues that patients with chemotherapy deal with. The introduction of more recent medications including Cinvanti, Sustol, and Varubi is to blame for the rise. However, the overall CINV medicines sales would be impacted by the patent expiry of important antiemetic medications like Emend. During the projection period, the growth of the opioid segment is anticipated to slow. Opioid medicines are subject to strict controls imposed by governments in many nations, including the US government. As a result, the rate of opioid medicine prescriptions has dramatically decreased.

Based on application, the cancer supportive care drugs market has been divided into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others.

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies.

The cancer supportive care drugs market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The launch and quick adoption of biosimilars as well as curbs on the prescription of opioids are likely to cause the market in North America and other developed regions to contract over the course of the forecast period. Additionally, tailored, targeted medicines are widely used in these regions due to their lower incidence of adverse effects, increasing public knowledge of their availability, and supportive reimbursement practises for expensive targeted therapies. High unmet needs for cancer supportive care exist in developing nations such those in the Middle East and Africa, Latin America, and Asia-Pacific. Chemotherapy is still a common treatment because of the underdeveloped healthcare systems and low levels of disposable income in these areas. These elements are anticipated to fuel market expansion in these regions.

Get access to a deeper coverage of the impact of COVID-19 on this Market here:https://www.stratviewresearch.com/Request-Sample/3140/cancer-supportive-care-drugs-market.html#form

About Stratview Research

Stratview Research is a global market intelligence firm providing wide range of services including syndicated market reports, custom research and sourcing intelligence across industries, such as Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas.

For enquiries,
Contact:
Stratview Research
E-mail: 
sales@stratviewresearch.com
Direct: +1-313-307-4176

 

The comments are closed.